Methyldopa Market

The Methyldopa market is anticipated to grow at a CAGR of 3.4% between 2025 and 2035, largely driven by its continued use in managing hypertension during pregnancy. As one of the safest antihypertensive agents for expectant mothers, Methyldopa maintains an essential role in obstetric care protocols worldwide. Despite the rise of newer antihypertensive medications, Methyldopa’s long-standing safety profile, affordability, and inclusion in the WHO’s essential medicines list ensure its relevance. Generic drug manufacturers continue to supply high-volume, cost-effective formulations to meet demand in both public and private healthcare systems, especially in developing regions.

Geographically, the highest demand for Methyldopa is concentrated in Asia-Pacific and Africa, where elevated birth rates and limited access to advanced antihypertensives strengthen its use for pregnancy-related hypertension. North America and Europe also use Methyldopa, though in more targeted applications within pregnancy care, especially when ACE inhibitors or ARBs are contraindicated. In Latin America and the Middle East, increased emphasis on maternal health through public healthcare programs supports moderate growth in Methyldopa uptake, especially via government tenders and hospital procurement.

The market report is evolving with a cornerstone drug in pregnancy-related hypertension management. Its stability, low cost, and safety keep it in demand despite modern alternatives. Manufacturers capable of delivering compliant, large-scale production, especially for government health programs and maternal care, will benefit from consistent long-term market presence.